<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">farmaec</journal-id><journal-title-group><journal-title xml:lang="en">FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology</journal-title><trans-title-group xml:lang="ru"><trans-title>ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2070-4909</issn><issn pub-type="epub">2070-4933</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2070-4909.2016.9.1.079-083</article-id><article-id custom-type="elpub" pub-id-type="custom">farmaec-139</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Methodology</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Методология</subject></subj-group></article-categories><title-group><article-title>PROSPECTS FOR THE USE OF METHODS OF ECONOMIC EVALUATION AT THE STAGE OF PLANNING AND ORGANISATION OF CLINICAL TRIALS</article-title><trans-title-group xml:lang="ru"><trans-title>Перспективы применения методов клинико-экономического анализа на этапе планирования и организации клинических исследований</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мусина</surname><given-names>Н. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Musina</surname><given-names>N. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.ф.н., доцент кафедры фармакологии фармацевтического факультета, ул. Трубецкая, д. 8, стр. 2, Москва, 119991;</p><p>начальник отдела развития и внешних коммуникаций, Хохловский пер., д. 10, стр. 5, Москва, 109028</p></bio><bio xml:lang="en"><p>PhD, lecturer of the Department of Pharmacology, Pharmaceutical Faculty, ul. Trubetskaya, 8-2, Moscow, 119048;</p><p>Chief of development and communications, Center of Healthcare Quality Assessment and Control, Khokhlovsky per., 10-5, Moscow, 109028</p></bio><email xlink:type="simple">nuriyamusina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тарасов</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Tarasov</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.ф.н., заведующий кафедрой фармакологии,</p><p>ул. Трубецкая, д. 8, стр. 2, Москва, 119991</p></bio><bio xml:lang="en"><p>Head of the Department of Pharmacology, Pharmaceutical Faculty, ul. Trubetskaya, 8-2, Moscow, 119048</p></bio><email xlink:type="simple">tarasov-v-v@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГБОУ ВПО «Первый Московский государственный медицинский университет&#13;
 имени И.М. Сеченова» Минздрава России;&#13;
ФГБУ «Центр экспертизы и контроля качества медицинской продукции»&#13;
 Минздрава России<country>Россия</country></aff><aff xml:lang="en">First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation;&#13;
Quality examination and control of medical products Centre of the Russian Federation Ministry of Health<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ГБОУ ВПО «Первый Московский государственный медицинский университет&#13;
 имени И.М. Сеченова» Минздрава России<country>Россия</country></aff><aff xml:lang="en">First Moscow State Medical Sechenov University of the Ministry of Health Russian Federation<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>12</day><month>04</month><year>2016</year></pub-date><volume>9</volume><issue>1</issue><fpage>79</fpage><lpage>83</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Musina N.Z., Tarasov V.V., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Мусина Н.З., Тарасов В.В.</copyright-holder><copyright-holder xml:lang="en">Musina N.Z., Tarasov V.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacoeconomics.ru/jour/article/view/139">https://www.pharmacoeconomics.ru/jour/article/view/139</self-uri><abstract><p>The article describes a new approach to the use of economic evaluation at the stage of planning and organization of clinical trials and considers the examples of studies which undertook this approach. The use of economic evaluation before clinical trials enables to assess the necessity of undertaking of the clinical trial and formulate the recommendations regarding the appropriate trial design, increasing its costeffectiveness.</p></abstract><trans-abstract xml:lang="ru"><p>В статье описывается новый подход по применению клинико-экономического анализа на этапе планирования клинических исследований, а также приводятся примеры исследований, реализовавших данный подход. Применение методов клинико-экономического анализа на этапе планирования позволяет оценить целесообразность и необходимость проведения клинического исследования, а также дать рекомендации по оптимальному дизайну исследования для достижения максимальной экономической эффективности и снижению затрат на проведение.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>клинико-экономический анализ</kwd><kwd>планирование клинических исследований</kwd><kwd>разработка и исследование в медицине</kwd></kwd-group><kwd-group xml:lang="en"><kwd>economic evaluation</kwd><kwd>clinical trial planning</kwd><kwd>medical research and development</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ассоциация организаций по клиническим исследованиям (АОКИ). Информационно-аналитический бюллетень. URL: http://acto-russia.org/index.php?option=com_content&amp;task=view&amp;id=260. Дата обращения: 10.09.2015.</mixed-citation><mixed-citation xml:lang="en">The Association of Clinical Research Organizations (ACTO). Information-analytical bulletin. URL: http://acto-russia.org/index.php?option=com_content&amp;task=view&amp;id=260. Accessed: 10.09.2015.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Омельяновский В.В., Авксентьева М.В., Деркач Е.В., Свешникова Н.Д. Анализ стоимости болезни проблемы и пути решения. Педиатрическая фармакология. URL: http://cyberleninka.ru/article/n/analiz-stoimosti-bolezni-problemy-i-puti-resheniya. Дата обращения: 10.09.2015.</mixed-citation><mixed-citation xml:lang="en">Omelyanovskiy V.V., Avksentyeva M.V., Derkach E.V., Sveshnikova N.D. Pediatricheskaya farmakologiya. URL: http://cyberleninka.ru/article/n/analiz-stoimosti-bolezni-problemy-i-puti-resheniya. Accessed: 10.09.2015.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Фонд содействия развитию науки, образования и медицины. URL: http://fsrnom.ru/analytics/detail.php?ELEMENT_ID=239. Дата обращения: 10.09.2015.</mixed-citation><mixed-citation xml:lang="en">Fund for the Advancement of Science, Education and Medicine. URL: http://fsrnom.ru/analytics/detail.php?ELEMENT_ID=239. Accessed: 10.09.2015.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Altman D.G. Practical statistics for medical research. New York. 1990; 455-61.</mixed-citation><mixed-citation xml:lang="en">Altman D.G. Practical statistics for medical research. New York. 1990; 455-61.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Berger M L., Bingefors K., Hedblom E.C. et al. Torrance Health care cost, quality and outcomes. ISPOR book of terms. Torrance. New York. 2003.</mixed-citation><mixed-citation xml:lang="en">Berger M L., Bingefors K., Hedblom E.C. et al. Torrance Health care cost, quality and outcomes. ISPOR book of terms. Torrance. New York. 2003.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Drummond M.F., Sculpher M.J., Torrance G.W., O’Brien B.J. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford. 2005.</mixed-citation><mixed-citation xml:lang="en">Drummond M.F., Sculpher M.J., Torrance G.W., O’Brien B.J. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford. 2005.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gillespie W.J., Pekarsky B., O’Connel D.L. Evaluation of new technologies for total hip replacement: economic modeling and clinical trials. J Bone Joint Surg. 1995; 77B: 528-33.</mixed-citation><mixed-citation xml:lang="en">Gillespie W.J., Pekarsky B., O’Connel D.L. Evaluation of new technologies for total hip replacement: economic modeling and clinical trials. J Bone Joint Surg. 1995; 77B: 528-33.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Parsonett J., Harris R.A., Hack H.M., Owens D.K. Modelling cost effecriveness of Helicobacter screening to prevent gastric cancer: mandate for clinical trials. Lancet. 1996; 348: 150-4.</mixed-citation><mixed-citation xml:lang="en">Parsonett J., Harris R.A., Hack H.M., Owens D.K. Modelling cost effecriveness of Helicobacter screening to prevent gastric cancer: mandate for clinical trials. Lancet. 1996; 348: 150-4.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Torgerson P.D.J., Torgerson C.J. Designing Randomised trials in health, education and the social sciences: An introduction. United Kingdom. 2008; 108-111.</mixed-citation><mixed-citation xml:lang="en">Torgerson P.D.J., Torgerson C.J. Designing Randomised trials in health, education and the social sciences: An introduction. United Kingdom. 2008; 108-111.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Trends, Charts, and Maps – ClinicalTrials.gov. 2015. URL: https://www.clinicaltrials.gov/ct2/resources/trends. Дата обращения: 10.09.2015.</mixed-citation><mixed-citation xml:lang="en">Trends, Charts, and Maps – ClinicalTrials.gov. 2015. URL: https://www.clinicaltrials.gov/ct2/resources/trends. Accessed: 10.09.2015.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Torgerson D.J., Byford S. Economic modelling before clinical trials. BMJ. 2002; 325: 98.</mixed-citation><mixed-citation xml:lang="en">Torgerson D.J., Byford S. Economic modelling before clinical trials. BMJ. 2002; 325: 98.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
